JP2023540795A5 - - Google Patents
Info
- Publication number
- JP2023540795A5 JP2023540795A5 JP2023516052A JP2023516052A JP2023540795A5 JP 2023540795 A5 JP2023540795 A5 JP 2023540795A5 JP 2023516052 A JP2023516052 A JP 2023516052A JP 2023516052 A JP2023516052 A JP 2023516052A JP 2023540795 A5 JP2023540795 A5 JP 2023540795A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- pharmaceutical composition
- treatment
- composition according
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078211P | 2020-09-14 | 2020-09-14 | |
| US63/078,211 | 2020-09-14 | ||
| US202063106302P | 2020-10-27 | 2020-10-27 | |
| US63/106,302 | 2020-10-27 | ||
| US202163185357P | 2021-05-06 | 2021-05-06 | |
| US63/185,357 | 2021-05-06 | ||
| PCT/IB2021/058229 WO2022053990A1 (en) | 2020-09-14 | 2021-09-10 | Methods, therapies and uses for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540795A JP2023540795A (ja) | 2023-09-26 |
| JP2023540795A5 true JP2023540795A5 (enExample) | 2024-09-17 |
Family
ID=77989848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516052A Pending JP2023540795A (ja) | 2020-09-14 | 2021-09-10 | がんを処置するための方法、治療、および使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230340137A1 (enExample) |
| EP (1) | EP4211167A1 (enExample) |
| JP (1) | JP2023540795A (enExample) |
| KR (1) | KR20230069181A (enExample) |
| CN (1) | CN116194105A (enExample) |
| AU (2) | AU2021339096B2 (enExample) |
| BR (1) | BR112023003688A2 (enExample) |
| CA (1) | CA3194925A1 (enExample) |
| IL (1) | IL300884A (enExample) |
| MX (1) | MX2023003034A (enExample) |
| TW (1) | TWI914401B (enExample) |
| WO (1) | WO2022053990A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120390653A (zh) * | 2022-12-09 | 2025-07-29 | 辉瑞大药厂 | Cd47阻断剂及抗bcma/抗cd3双特异性抗体的组合疗法 |
| TW202504929A (zh) * | 2023-06-22 | 2025-02-01 | 美商建南德克公司 | 用於癌症治療之方法及組成物 |
| TW202523350A (zh) | 2023-08-10 | 2025-06-16 | 美商輝瑞股份有限公司 | 治療癌症之方法，療法及用途 |
| IL328139A (en) * | 2023-11-01 | 2026-06-01 | Janssen Biotech Inc | Methods for treating multiple myeloma |
| TW202532072A (zh) * | 2023-12-08 | 2025-08-16 | 美商西建公司 | 治療多發性骨髓瘤之療法 |
| WO2025122813A1 (en) * | 2023-12-08 | 2025-06-12 | Board Of Regents, The University Of Texas System | Protecting cell therapies from tgf-beta induced immunosuppression |
| WO2026059920A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
| WO2026105079A2 (en) * | 2024-11-18 | 2026-05-21 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| AP2379A (en) | 2004-03-23 | 2012-03-08 | Pfizer Prod Inc | Imidazole compounds for the treatment of neurodegenerative disorders. |
| SI2242771T1 (sl) | 2007-12-14 | 2013-09-30 | Bristol-Myers Squibb Company | Vezane molekule k humanemu ox40 receptorju |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| EP2780039B9 (en) | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI811023B (zh) * | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| IL313608A (en) * | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN111148762A (zh) | 2017-05-31 | 2020-05-12 | 斯特库伯株式会社 | 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途 |
| JP7234142B2 (ja) | 2017-06-02 | 2023-03-07 | ファイザー・インク | Ｆｌｔ３に特異的な抗体およびその使用 |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| MX2021001083A (es) * | 2018-07-31 | 2021-03-31 | Amgen Res Munich Gmbh | Regimen posologico para anticuerpos biespecificos contra bcma-cd3. |
| ES3009025T3 (en) * | 2018-08-31 | 2025-03-25 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies |
| CN112955748A (zh) * | 2018-10-31 | 2021-06-11 | 葛兰素史密斯克莱知识产权发展有限公司 | 治疗癌症的方法 |
| AU2020307471A1 (en) * | 2019-06-24 | 2022-01-27 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen |
| HUE068401T2 (hu) * | 2019-11-11 | 2024-12-28 | Amgen Res Munich Gmbh | A BCMA elleni hatóanyagok adagolási rendje |
| CN116249548A (zh) * | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| JP2023524854A (ja) * | 2020-05-13 | 2023-06-13 | ファイザー・インク | がんを処置するための方法、治療、および使用 |
-
2021
- 2021-09-10 KR KR1020237012640A patent/KR20230069181A/ko active Pending
- 2021-09-10 AU AU2021339096A patent/AU2021339096B2/en active Active
- 2021-09-10 MX MX2023003034A patent/MX2023003034A/es unknown
- 2021-09-10 JP JP2023516052A patent/JP2023540795A/ja active Pending
- 2021-09-10 US US18/025,879 patent/US20230340137A1/en active Pending
- 2021-09-10 WO PCT/IB2021/058229 patent/WO2022053990A1/en not_active Ceased
- 2021-09-10 BR BR112023003688A patent/BR112023003688A2/pt unknown
- 2021-09-10 EP EP21782599.1A patent/EP4211167A1/en active Pending
- 2021-09-10 CN CN202180062823.5A patent/CN116194105A/zh active Pending
- 2021-09-10 IL IL300884A patent/IL300884A/en unknown
- 2021-09-10 TW TW110133770A patent/TWI914401B/zh active
- 2021-09-10 CA CA3194925A patent/CA3194925A1/en active Pending
-
2026
- 2026-03-11 AU AU2026201847A patent/AU2026201847A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506550A5 (enExample) | ||
| JP2017523187A5 (enExample) | ||
| JP2019517549A5 (enExample) | ||
| JP2021517566A5 (enExample) | ||
| JP2018184417A5 (enExample) | ||
| JP2019521988A5 (enExample) | ||
| JP2023501375A5 (enExample) | ||
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2020500181A5 (enExample) | ||
| JP2019501886A5 (enExample) | ||
| JP2015500822A5 (enExample) | ||
| JP2015525798A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2015517511A5 (enExample) | ||
| RU2014127298A (ru) | Применения иммуноконъюгатов, мишенью которых является cd138 | |
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| RU2017128616A (ru) | Комбинированное лекарственное средство | |
| JP2015172060A5 (enExample) | ||
| JP2017537927A5 (enExample) | ||
| RU2020134307A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| JP2020158544A5 (enExample) | ||
| JP2025515092A5 (enExample) | ||
| JP2019519584A5 (enExample) | ||
| JP2021506817A5 (enExample) |